New Zealand - Ingliż - Ministry for Primary Industries

bayer new zealand limited - flufenacet; diflufenican - flufenacet 400 g/litre; diflufenican 200 g/litre - herbicide

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - loratadine 5mg (micronised);  ;   - chewable tablet - 5 mg - active: loratadine 5mg (micronised)     excipient: aspartame citric acid colloidal silicon dioxide fd & c red no. 27, aluminium lake (16-21%) c6527 grape bubblegum flavour 059145 ap0551 indigo carmine magnesium stearate mannitol microcrystalline cellulose sodium starch glycolate stearic acid - indicated for the relief of: · symptoms associated with seasonal and perennial allergic rhinitis, such as sneezing, nasal discharge and itching and ocular itching and burning. · symptoms and signs of chronic urticaria and other allergic dermatological disorders

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - loratadine 10mg - tablet - 10 mg - active: loratadine 10mg excipient: lactose monohydrate magnesium stearate maize starch - the treatment of seasonal allergic rhinitis in adults and children 12 years of age and older.

New Zealand - Ingliż - Ministry for Primary Industries

bayer new zealand limited - tebuconazole - water dispersible granule - tebuconazole 250 g/kg - fungicide - fungicide

New Zealand - Ingliż - Ministry for Primary Industries

bayer new zealand limited - bacillus subtilis qst 713 - wettable powder - bacillus subtilis qst 713 1.46 b cfu/g - fungicide - fungicide

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 20mg (plus 10% overage) - modified release tablet - 20 mg - active: nifedipine 20mg (plus 10% overage) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - treatment of coronary heart disease

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 33mg (active blend) - modified release tablet - 30 mg - active: nifedipine 33mg (active blend) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate as 0.4mg in active blend, 0.2mg in osmotic blend opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - treatment of coronary heart disease

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 66mg (active blend) - modified release tablet - 60 mg - active: nifedipine 66mg (active blend) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate as 0.8mg in active blend, 0.4mg in osmotic blend opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - -treatment of coronary heart disease -chronic stable angina pectoris (angina of effort) - treatment of hypertension

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 90mg - modified release tablet - 90 mg - active: nifedipine 90mg excipient: cellulose acetate hyprolose hypromellose   iron oxide red   macrogol 3350 magnesium stearate polyethylene oxide propylene glycol sodium chloride titanium dioxide

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - dexchlorpheniramine maleate 2mg;  ; dexchlorpheniramine maleate 2mg - film coated tablet - 2 mg - active: dexchlorpheniramine maleate 2mg   excipient: lactose monohydrate magnesium stearate maize starch starch active: dexchlorpheniramine maleate 2mg excipient: lactose monohydrate magnesium stearate maize starch starch